Table 1.
Demographic and clinical characteristics of maternal participants by vaccine platform.
| Overall (N = 158) | Ad26.COV2.S (N = 28) | mRNA-1273 (N = 61) | BNT162b2 (N = 69) | P | |
|---|---|---|---|---|---|
| Maternal age, years | 34 [32, 36] | 34 [32, 36] | 33 [32, 36] | 34 [32, 36] | 0.78 |
| Gravidity | 2 [1, 3] | 2 [2, 3] | 2 [1, 3] | 2 [1, 3] | 0.27 |
| Parity | 1 [0, 1] | 1 [0, 1] | 1 [0, 1] | 1 [0, 1] | 0.73 |
| Race (%) | |||||
| Asian | 9 (6) | 1 (4) | 3 (5) | 5 (7) | 0.36 |
| Black or African American | 4 (3) | 2 (7) | 1 (2) | 1 (1) | |
| Other | 6 (4) | 3 (11) | 2 (3) | 1 (1) | |
| Unknown/not reported | 3 (2) | 1 (4) | 1 (2) | 1 (1) | |
| White | 135 (85) | 21 (75) | 54 (89) | 60 (87) | |
| American Indian or Alaskan native | 1 (1) | 0 (0) | 0 (0) | 1 (1) | |
| Ethnicity (%) | |||||
| Hispanic | 9 (6) | 4 (14) | 3 (5) | 2 (3) | 0.02 |
| non-Hispanic | 141 (89) | 20 (71) | 57 (93) | 64 (93) | |
| Unknown/not reported | 8 (5) | 4 (14) | 1 (2) | 3 (4) | |
| Insurance status (%) | |||||
| Private | 152 (96) | 25 (89) | 61 (100) | 66 (96) | 0.05 |
| Public | 5 (3) | 3 (11) | 0 (0) | 2 (3) | |
| Unknown | 1 (1) | 0 (0) | 0 (0) | 1 (1) | |
| Pre-pregnancy BMI, kg/m2 | 24 [22, 27] | 23 [22, 27] | 23 [22, 27] | 24 [22, 26] | 1.00 |
| Obesity (%) | |||||
| No | 118 (75) | 22 (79) | 42 (69) | 54 (78) | 0.47 |
| Yes | 40 (25) | 6 (21) | 19 (31) | 15 (22) | |
| Autoimmune condition (%) | |||||
| No | 152 (96) | 28 (100) | 58 (95) | 66 (96) | 0.74 |
| Yes | 6 (4) | 0 (0) | 3 (5) | 3 (4) | |
| Prior infection with SARS-CoV-2a (%) | |||||
| No | 153 (97) | 26 (93) | 58 (95) | 69 (100) | 0.06 |
| Yes | 5 (3) | 2 (7) | 3 (5) | 0 (0) | |
| Trimester of vaccination (%) | |||||
| First | 18 (11) | 2 (7) | 7 (11) | 9 (13) | 0.05 |
| Second | 88 (56) | 13 (46) | 42 (69) | 33 (48) | |
| Third | 52 (33) | 13 (46) | 12 (20) | 27 (39) | |
| Time from vaccination to sample collectionb, days | 50 [27, 86] | 58 [38, 85] | 62 [27, 91] | 42 [22, 74] | 0.10 |
BMI body mass index.
aFour participants tested positive for SARS-CoV-2 prior to vaccination and one participant tested positive at delivery.
bDefined time from a single dose of Ad26.COV2.S vaccine or second dose of mRNA-1273 or BNT162b2 and sample collection. Continuous variables presented as median [IQR] and categorical variables as n (%). Differences between groups assessed by Kruskal–Wallis (continuous) or Fisher’s exact test (categorical).